ERCC1 and non-small cell lung carcinoma: Furthermore, our previous research showed that the miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small-cell lung cancer cells, highlighting the mechanism of how microRNA 495 downregulates UBE2C [37].